Pharmaceutical US biotech company Biogen Idec and US pharma giant AbbVie have announced the full results from the Phase III DECIDE clinical trial, which show Zinbryta (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to Biogen's multiple sclerosis drug Avonex (interferon beta-1a). 18 September 2014